[ Price : $8.95]
New trial data show Eli Lillys Jaypirca (pirtobrutinib) significantly extended progression-free survival in previously untreated p...[ Price : $8.95]
Merck reports favorable results from the IDeate-Lung01 Phase 2 trial showing that ifinatamab deruxtecan demonstrated clinically me...[ Price : $8.95]
FDA issues Saol Therapeutics a complete response letter on its NDA for SL1009 (sodium dichloroacetate oral solution) for treating ...[ Price : $8.95]
FDA unveils a new green list import alert aimed at preventing unapproved and potentially unsafe GLP-1 drug ingredients from enteri...[ Price : $8.95]
FDA grants CERo Therapeutics fast track status for CER-1236 and its use for treating acute myeloid leukemia.[ Price : $8.95]
Johns Hopkins drug safety expert G. Caleb Alexander says FDAs recent use of ad hoc expert panels in place of traditional advisory ...[ Price : $8.95]
FDA commissioner Marty Makary says an evaluation of reports contained in the agencys vaccines adverse event database shows there h...[ Price : $8.95]
BioNTech and Duality Biologics report that trastuzumab pamirtecan met its primary endpoint in a pivotal Phase 3 trial for patients...